| Theme | NASH 2018 | |
|---|---|---|
| Title | Biomarkers for the Diagnosis of NASH | |
| Publish Date | 2018/01 | |
| Author | Yoshio Sumida | Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University / Japan Strategic Medical Administration Research Center, Division of Clinical Research and Development, Japan Study Group of NAFLD (JSG‒NAFLD) |
| Author | Yoshihiro Kamada | Departments of Molecular Biochemistry & Clinical Investigation, Osaka University, Graduate School of Medicine / Gastroenterology and Hepatology, Osaka University, Graduate School of Medicine / Japan Strategic Medical Administration Research Center, Di |
| Author | Masato Yoneda | Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine / Japan Strategic Medical Administration Research Center, Division of Clinical Research and Development, Japan Study Group of NAFLD (JSG‒NAFLD) |
| Author | Masafumi Ono | Department of Gastroenterology and Hepatology, Kochi Medical School / Japan Strategic Medical Administration Research Center, Division of Clinical Research and Development, Japan Study Group of NAFLD (JSG‒NAFLD) |
| Author | Yuichiro Eguchi | Liver Center, Saga University Hospital / Japan Strategic Medical Administration Research Center, Division of Clinical Research and Development, Japan Study Group of NAFLD (JSG‒NAFLD) |
| Author | Masashi Yoneda | Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University / Japan Strategic Medical Administration Research Center, Division of Clinical Research and Development, Japan Study Group of NAFLD (JSG‒NAFLD) |
| [ Summary ] | It is estimated that one fourth of the adult population is affected by nonalcoholic fatty liver disease (NAFLD) worldwide. Liver biopsy is the gold standard for diagnosing nonalcoholic steatohepatitis (NASH). NASH patients are at high risk of liver‒related mortality. However, liver biopsy also has many related problems, including sampling error, observers' variability, cost, and risk of complications. Moreover, it is not realistic to perform liver biopsy in every NAFLD patient. Although noninvasive diagnosis of NASH using various biomarkers has recently been attempted, it is rather important to predict the severity of hepatic fibrosis. The NAFLD fibrosis score and the FIB‒4 index are useful for excluding NASH with advanced fibrosis or predicting liver related mortality. It is required to predict over‒all mortality and hepatocarcinogenesis. | |